{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:27:10Z","timestamp":1790940430121,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2006,9,28]],"date-time":"2006-09-28T00:00:00Z","timestamp":1159401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effects of oral salmon calcitonin (sCT) on Lequesne's algofunctional index scores and on biomarkers of joint metabolism in knee osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, double\u2010blind trial, patients received either placebo (n = 18), 0.5 mg of sCT (n = 17), or 1 mg of sCT (n = 18) daily for 84 days. Biomarkers included C\u2010telopeptide of type II collagen (CTX\u2010II), type II collagen neoepitope C2C, collagenases (matrix metalloproteinase 1 [MMP\u20101], MMP\u20108, and MMP\u201013), stromelysin (MMP\u20103), tissue inhibitors of metalloproteinases 1 and 2, and hyaluronan. Statistical analysis included nonparametric tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 41 patients completed the study (13 in the group receiving 0.5 mg of sCT and 14 in each of the other 2 other groups). Although, on day 84, patients in both the placebo group and the group receiving 1 mg of sCT exhibited a similar significant decrease in pain scores, a significant reduction in the function score was observed only in the 2 sCT groups. On day 84, there was no significant decrease in biomarker levels in the placebo group, whereas significant reductions in the levels of both MMP\u20103 and hyaluronan were observed in the 2 sCT groups. The group of patients receiving 1 mg of sCT exhibited significant decreases in the levels of CTX\u2010II, C2C, and MMP\u201013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By improving functional disability and by reducing levels of biomarkers that are thought to be predictive of joint space narrowing (and thus cartilage loss), oral sCT at a dose of 1 mg might be a useful pharmacologic agent in human knee OA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.22075","type":"journal-article","created":{"date-parts":[[2006,9,28]],"date-time":"2006-09-28T12:59:23Z","timestamp":1159448363000},"page":"3205-3211","source":"Crossref","is-referenced-by-count":119,"title":["Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis"],"prefix":"10.1002","volume":"54","author":[{"given":"Daniel\u2010Henri","family":"Manicourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo\u00efse","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mindeholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.\u2010M.","family":"Thonar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Pierre","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,28]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"285","article-title":"Rationale for the potential use of calcitonin in osteoarthritis","volume":"5","author":"Manicourt DH","year":"2005","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040715"},{"key":"e_1_2_6_4_2","first-page":"779","article-title":"The algofunctional indices for hip and knee osteoarthritis","volume":"24","author":"Lequesne MG","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_2","first-page":"1648","article-title":"Outcome variables for osteoarthritis clinical trials: the OMERACT\u2010OARSI set of responder criteria","volume":"30","author":"Pham T","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10576"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20332"},{"key":"e_1_2_6_8_2","first-page":"223","volume-title":"Arthritis and allied conditions: a textbook of rheumatology","author":"Poole AR","year":"2005"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21345"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1042\/bss0700115"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.16.4.494"},{"key":"e_1_2_6_12_2","first-page":"456","volume-title":"Osteoarthritis","author":"Schauwecker DS","year":"2003"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21122"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.04.032"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21124"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22075","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T17:31:15Z","timestamp":1698773475000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,28]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1002\/art.22075"],"URL":"https:\/\/doi.org\/10.1002\/art.22075","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1139041.596149","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,28]]}}}